Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Prostatic Diseases × talazoparib × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 13 Pancreatic Neoplasms 3 Carcinoma, Renal Cell 3 Breast Neoplasms 3 Sarcoma, Ewing 2 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Colorectal Neoplasms 2 Wilms Tumor 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Prostatic Diseases 1 Prostate Cancer Metastatic 1 Osteosarcoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neuroblastoma 1 Neoplasms 1 Metastatic Castration Resistant Prostate Cancer (mCRPC) 1 Kidney Neoplasms 1 Hepatoblastoma 1 Fanconi Anemia, Complementation Group D1 1 Carcinoma, Transitional Cell 1 Carcinoma, Ovarian Epithelial 1 Adenocarcinoma 1

Interventions

padeliporfin 5 darolutamide 3 Pluvicto 3 gallium 68 PSMA-11 2 enzalutamide 2 apalutamide 2 Radiotherapy 2 Nivolumab 2 Androgen Antagonists 2 Abiraterone Acetate 2 talazoparib 1 sipuleucel-T 1 palladium-bacteriopheophorbide 1 onapristone 1 olaparib 1 niraparib 1 luprolide acetate gel depot 1 ixabepilone 1 gedatolisib 1 abiraterone 1 Therapeutics 1 Tamsulosin 1 Surveys and Questionnaires 1 Standard of Care 1 Robotic Surgical Procedures 1 Prostate-Specific Antigen 1 Prednisone 1 Paclitaxel 1 Oxygen 1 Nitrous Oxide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06582628 2024-12-02

TEAM PC

Fundacion Oncosur

Phase 2 Recruiting

Prostatic Diseases, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡